Valneva (NASDAQ:VALN) Shares Gap Down - Time to Sell?

Key Points

• Valneva's stock price dropped significantly, opening at $9.12 down from a previous close of $11.64, ultimately trading at $9.06 with a volume of 151,118 shares.
• Despite the recent drop, analysts maintain a mixed outlook with an average target price of $16.00 and a "Buy" rating from two equities research analysts.
• In its latest earnings report, Valneva beat analysts' estimates by posting ($0.16) earnings per share against expectations of ($0.27), with revenues of $54.84 million.

Shares of Valneva SE Sponsored ADR (NASDAQ:VALN - Get Free Report) gapped down before the market opened on Monday . The stock had previously closed at $11.64, but opened at $9.12. Valneva shares last traded at $9.06, with a volume of 151,118 shares.

Analyst Upgrades and Downgrades

VALN has been the subject of a number of research analyst reports. Guggenheim dropped their price objective on Valneva from $15.00 to $14.00 and set a "buy" rating for the company in a report on Thursday, May 8th. HC Wainwright initiated coverage on Valneva in a report on Tuesday, August 19th. They set a "buy" rating and a $18.00 price objective for the company. Two equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Valneva currently has an average rating of "Buy" and an average target price of $16.00.

Valneva Trading Down 19.2%

The company has a current ratio of 2.27, a quick ratio of 1.77 and a debt-to-equity ratio of 0.66. The business's 50-day simple moving average is $7.41 and its two-hundred day simple moving average is $6.97. The company has a market capitalization of $800.27 million, a PE ratio of -9.60 and a beta of 1.77.

Valneva (NASDAQ:VALN - Get Free Report) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.16) earnings per share for the quarter, beating analysts' consensus estimates of ($0.27) by $0.11. Valneva had a negative net margin of 33.87% and a negative return on equity of 34.78%. The company had revenue of $54.84 million during the quarter, compared to analysts' expectations of $46.28 million. On average, analysts predict that Valneva SE Sponsored ADR will post 0.13 earnings per share for the current year.

Hedge Funds Weigh In On Valneva

Large investors have recently modified their holdings of the stock. Wells Fargo & Company MN lifted its position in shares of Valneva by 14.3% during the fourth quarter. Wells Fargo & Company MN now owns 246,766 shares of the company's stock worth $1,079,000 after purchasing an additional 30,859 shares during the last quarter. GAMMA Investing LLC bought a new position in shares of Valneva during the first quarter worth about $94,000. Marex Group plc bought a new position in shares of Valneva during the second quarter worth about $64,000. Finally, Frazier Life Sciences Management L.P. bought a new position in Valneva in the second quarter worth about $8,240,000. Institutional investors own 11.39% of the company's stock.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.